Tempus/Personalis xM (NeXT Personal Dx) Test

Tempus and Personalis said this week that Tempus has officially launched the xM (NeXT Personal Dx) Test, developed by Personalis. The new ultra-sensitive, tumor-informed minimal residual disease (MRD) and monitoring test is based on whole-genome sequencing and can detect small traces of circulating tumor DNA (ctDNA) in the blood of patients with early non-small cell lung cancer (NSCLC) and breast cancer following curative intent treatment. The test can also be used for immunotherapy monitoring in late-stage cancer across all solid tumors. The assay identifies up to 1,800 somatic variants unique to a patient's tumor, supporting physicians in making informed, individualized patient-management decisions.

Tempus and Personalis are co-commercializing the assay under an agreement announced last fall. The assay also supplements Tempus' own xM MRD assay, which it launched earlier this year to detect circulating tumor DNA in the blood of patients with early-stage colorectal cancer after surgery.